High-risk patients with hematuria are not evaluated according to guideline recommendations

Cancer

Volumn 116, Issue 12, 2010, Pages 2954-2959

  Elias, Keren ^a   Svatek, Robert S ^a   Gupta, Samir ^a,b   Ho, Richard ^a   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Guidelines recommendations; Hematuria

Indexed keywords

ADULT; ARTICLE; BLADDER CANCER; CANCER SCREENING; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; CYSTOSCOPY; ENVIRONMENTAL EXPOSURE; HEMATURIA; HIGH RISK PATIENT; HUMAN; INFECTION; INTRAVENOUS PYELOGRAPHY; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; URINALYSIS; URINE CULTURE; URINE CYTOLOGY;

CYTOLOGICAL TECHNIQUES; DIAGNOSTIC IMAGING; FEMALE; HEMATURIA; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PRACTICE GUIDELINES AS TOPIC; REFERRAL AND CONSULTATION; RISK; SMOKING; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 77953989943     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25048     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Grossfeld GD, Litwin MS, Wolf JS, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy - part I: definition, detection, prevalence, and etiology. Urology. 2001; 57:599-603.
3. Messing EM, Young TB, Hunt VB, et al. Hematuria home screening: repeat testing results. J Urol. 1995;154:57-61.
4. Mariani AJ, Mariani MC, Macchioni C, Stams UK, Hariharan A, Moriera A. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol. 1989;141:350-355.
5. Cohen RA, Brown RS. Clinical practice. Microscopic hematuria. N Engl J Med. 2003;348:2330-238.
6. Grossfeld GD, Litwin MS, Wolf JS Jr, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy - part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology. 2001;57:604-610.
7. Nieder AM, Lotan Y, Nuss GR, et al. Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. Urol Oncol. 2008.
8. Johnson EK, Daignault S, Zhang Y, Lee CT. Patterns of hematuria referral to urologists: does a gender disparity exist? Urology. 2008;72:498-502; discussion 502-503.
9. Lotan Y, Elias K, Svatek RS, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol. 2009;182: 52-57; discussion 58.
10. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000;163: 524-527. (Pubitemid 30060509)
11. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 1992;6:1-30.
12. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89:630-639. (Pubitemid 30640110)
13. Samanic C, Kogevinas M, Dosemeci M, et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev. 2006;15:1348-1354.
14. Wallace DM, Raghavan D, Kelly KA, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol. 1991;67:608-615.
15. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
16. Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst. 2005;97:989-997.
17. Jimbo M, Myers RE, Meyer B, et al. Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med. 2009;7:11-16.
18. Singh H, Kadiyala H, Bhagwath G, et al. Using a multifaceted approach to improve the follow-up of positive fecal occult blood test results. Am J Gastroenterol. 2009;104:942-952.
19. Rao SK, Schilling TF, Sequist TD. Challenges in the management of positive fecal occult blood tests. J Gen Intern Med. 2009;24:356-360.